Goflikicept

DB16396InvestigationalProtein Based Therapies

Goflikicept is under investigation in clinical trial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe...

Mechanism: Goflikicept is a fusion protein that neutralizes interleukin-1B (IL-1B), affecting its signalling pathways. As IL-1B is involved in 'cytokine storm' efects, goflikicept's effects on the molecule inhibits widespread inflammation.
Curator reviewed
Also known as: Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein
Code names: RPH-104

Resolves to

Compound

UNII11DRN01OK2CAS2416984-26-2

Clinical / RWD

ATCL04AC26

Targets

P01584IL1B

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 4 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Goflikicept, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account